^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo

Published date:
08/28/2021
Excerpt:
In vivo studies demonstrated afatinib (30 mg/kg) and AZD9291 (25 mg/kg) could significantly reduce the LCBM in vivo and increase survival percentages of treated mice compared with mice treated with vehicle and gefitinib (6.25 mg/kg)....In conclusion, our study demonstrated gefitinib + ABT263/ABT199, afatinib, and AZD9291 have clinical potential to treat LCBM.
DOI:
10.1007/s00204-021-03147-4